ABSTRACT
Diabetes is a common condition with a dismal prognosis. According to the International Diabetes Federation, 537 million people worldwide have diabetes. Cardiovascular disorders (CVD) are the major cause of death globally. Diabetes mellitus type 2 (T2DM) increases the risk of CVD. Since 2008, the FDA has required all new antihyperglycemic treatments to show no increased CV risk. Years of glucocentric diabetic therapy have left many patients on medicines with no known CV benefit. GLP-1 receptor agonists (GLP-1RAs) are excellent glucose-lowering medicines with little risk of hypoglycaemia, CVD and weight loss. GLP-1RAs may also delay renal disease development. As an adjunct to metformin or ongoing therapy, GLP1RAs or sodium-glucose cotransporter-2 inhibitors are recommended by the American Diabetes Association and the European Association for the Study of Diabetes (EASD). Thus, this review summarises GLP-1RA and their significance in the paradigm shift in diabetes care recommendations from glucocentric to gluco-cardiocentric
ABSTRACT
@#Dyslipidemia is a causal risk factor of atherosclerotic cardiovascular disease(ASCVD),and lipid-lowering therapies play a major role in preventing and managing ASCVD. Proprotein convertase subtilisin/kexin type 9(PCSK9)promotes atherosclerosis by increasing low-density lipoprotein cholesterol(LDL-C)and inflammatory response,while PCSK9 inhibitors can target to reduce PCSK9 levels and have high lipid lowering efficiency. Especially on the basis of statin or ezetimibe treatment,it can also bring more clinical benefits. With the in-depth study,PCSK9 inhibitor has become the research focus in recent years. This paper reviewed the development progress of PCSK9 inhibitors,in order to provide references for the clinical application of this class of drugs.
ABSTRACT
Background: Diabetes is a chronic metabolic disorder that is characterized by high level of blood glucose levels, which over a period of time can lead to micro-vascular or macro-vascular complications. Erectile dysfunction (ED) is common not much discussed and distressing complication of diabetes. ED in type 2 may be independent marker of coronary artery disease (CAD).Aim and objectives were to assess the ED in subject of type 2 diabetes mellitus (DM). Assessment of correlation of ED with CAD. Methods: The present cross-sectional study consisted total 180 diabetic patients. On basis of international index of erectile function (IIEF) questionnaire EDpatients were assessed.Result: Out of180 diabetic patients 36.11% had varying degree of ED. Out of 65 EDpatients, maximum frequency of moderate ED (47.69%) was found then severe ED (32.30%), mild to moderate ED (12.30%) and mild ED (7.69%). Most of the patients were in the age group of 40-50 years35 (53.84%), 50-60 years22(33.4%), <40 years(9.23%) and 60-70 years 2 (3.07%) showed ED. Fasting blood sugar and postprandial blood sugar showed significant (p<0.05) relation with ED. HbA1c show an insignificant correlation (p>0.05) with ED. In patient with ED was having more value of atherosclerotic cardiovascular disease (ASCVD) (9.11±4.84) than patient without ED (8.82±5.72). There was no significant (p>0.05) difference in term of ASCVD risk score in ED patient’s ED and without ED patients.Conclusions: Poor glycemiccontrol was a strongest risk factor for ED.
ABSTRACT
【Objective】 To investigate the level of atherosclerotic cardiovascular disease (ASCVD) related indexes in plasma donors from longevity area, and explore its influencing factors. 【Methods】 1 027 plasma donors from longevity hotspot (Bama, Guangxi province) and 1 816 donors from non-longevity region (Shimen, Hunan province) who donated plasma during June to November 2018 were randomly selected. Triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDLC), low density lipoprotein cholesterol (LDLC), apolipoprotein A1 (Apo-A1), apolipoprotein B (Apo-B), and fructosamine (FUN) of the two groups were measured and statistically analyzed. 【Results】 Compared with the non-longevity region group, the TG, TC and FUN levels of longevity hotspot group were lower (1.41±0.96 vs 2.31±1.28, 3.89±0.92 vs 4.04±0.82, 176.65±26.60 vs 200.33±34.19; all P<0.05), but HDLC, LDLC, Apo-A1 and Apo-B levels were higher (1.11±0.32 vs 0.96±0.25, 2.53±0.70 vs 2.29±0.56, 1.56±0.28 vs 1.23±0.18, 0.80±0.27 vs 0.72±0.19; all P<0.05). The yield (%) of high TG(12.0 vs 40.01) and FUN(0.58 vs 2.48), low HDLC(24.63 vs 43.90) and Apo-A1(1.66 vs 22.56) were lower in longevity area than those in non-longevity region (all P<0.05), but high LDLC(2.73 vs 0.28) and Apo-B(4.09 vs 0.22) yield(%) were higher in longevity area group ( P<0.05). The levels of TC, HDLC, LDLC, Apo-A1 and Apo-B were significantly different by ages (all P < 0.01), presenting positively correlated with age, significantly by gender and nationality, and slightly by blood type. 【Conclusion】 The ASCVD indexes of plasma donors from Bama were different from those from Shimen. Age, nationality, gender and blood type of donors from Bama all had a certain influence on these indexes levels.
ABSTRACT
Objective:To analyze active components， its targets and signaling pathways of Shenlian formula based on network pharmacology， and explore the molecular mechanism of Shenlian formula in the treatment of atherosclerotic cardiovascular disease （ASCVD）， in order to provide a basis for the rational interpretation of the prescription compatibility of Shenlian formula. Method:Major chemical compounds of the formula were obtained by SymMap and Systematic pharmacology database and analysis platform of Traditional Chinese Medicine （TCMSP）， its target proteins were obtained by SymMap and ETCM Databases， and the pathogenic genes responsible for of ASCVD were obtained by DisGeNET and GEO Datebases. Protein targets of drugs and pathogenic genes of diseases were overlapped to obtain predicted targets of Shenlian Formula for ASCVD. Proteins-proteins interactions （PPI） network was built through the String Datebase. The Cytoscape 3.6.0 was used to explore the key compounds and targets of Shenlian formula on ASCVD. Then gene ontology （GO） enrichment and Kyoto Encyclopedia of Genes and Genomes （KEGG） signaling pathway were analyzed to screen out the key targets of Shenlian Formula. Rat I/R model was adopted as representative disease model of ASCVD for experimental verification. Result:There were 59 candidate compounds， 67 predicted targets and 29 key targets of Shenlian formula on ASCVD. Key targets mainly included cyclooxygenase 2 （PTGS2）， estrogen receptor 1 （ESR1） and TP53. GO analysis showed that the biological functions of potential genes of Shenlian formula in treatment of ASCVD were mainly related to apoptotic， nitric oxide biosynthetic process， response to estradiol， angiogenesis， inflammatory response and oxidative stress and acute-phase response. KEGG pathway enrichment results showed that the pathways of potential genes of Shenlian formula in treatment of ASCVD mainly involved TNF signaling pathway， phosphatidylinositol-3 kinase （PI3K）/ protein kinase B （Akt） signaling pathway， hypoxia induction factor-1 （HIF-1） signaling pathway and apoptosis. Among them， the regulatory effect of Shenlian formula on apoptosis may act on not only TP53， but also different signaling pathways of apoptosis respectively， thus playing a synergistic effect. <italic>In vivo</italic> experimentation confirmed that Shenlian formula could significantly reduce the myocardial infarction area， improve the myocardial histopathological changes， and especially reduce myocardial mitochondrial injury. Further analysis showed that Shenlian formula can significantly inhibit the expressions of activated proteins in mitochondrial apoptosis pathway. Conclusion:Anti-atherosclerosis traditional Chinese medicine Shenlian formula could effectively intervene ASCVD， and its effect on mitochondrial apoptosis of myocardial cells is one of its mechanisms in protecting myocardial ischemia-reperfusion injury.
ABSTRACT
Objective: To assess the individual’s predicted risk of developing a CVD event in 10 y using risk scores among persons with other disorders/diseases. Methods: This is a cross-sectional observational study conducted for a period of 6 mo among 283 subjects. Total risk was estimated individually by using Framingham Risk Scoring Algorithm and ASCVD risk estimator. Results: According to Framingham Risk score the prevalence of low risk (<10%) identified as 67.84% (192), followed by intermediate risk (10%-19%), 19.08% (54), and high risk (≥20%) 13.07% (37). By using ASCVD Risk estimator, risk has reported in our study population was low risk (<5%) is 48.76% (138), borderline risk (5-7.4%) is 13.07% (37), intermediate risk (7.5-19.9%) is about 25.09% (71), high risk (>20%) is about 13.07% (37). Conclusion: In this study burden of CVD risk was relatively low, which was estimated by both the Framingham scale and ASCVD Risk estimator. Risk scoring of individuals helps us to identify the patients at high risk of CV diseases and also helps in providing management strategies.
ABSTRACT
Background@#Monocyte / High Density Lipoprotein Ratio (MHR) has become an inflammation marker of atherosclerotic cardiovascular diseases and is a handy and reliable diagnostic marker at a low cost. @*Objectives@#to suggest MHR as a new inflammation marker for ASCVDs by comparing it with other risk factors of cardiovascular disease and assessing the significance in screening@*Methods@#This study conducted during October to December 2019 is a hospital-based cross sectional study, with a total of 396 clients, all 20 to 64 years old, were selected as subjects of the study using a certain criteria. @*Results@#78.47% of the male subjects and 34.31% of female subjects were diagnosed with dislipidemia, which shows us that males were diagnosed more frequently. The study sample consisted of 274 (72.87%) men and 102 (27.13%) women with mean age of 36.6±8.42 years (range, 20-64 years), 78.47% were male and 34.31% were females. 66.49% of total participants were newly diagnosed with dyslipidemia. An age group of 30 to 40 years old were recorded with the highest cases of dyslipidemia. Monocyte / High Density Lipoprotein Ratio (MHR) were 7.88 and 12.82 in dyslipidemic and non-dyslipidemic subjects, respectively and showed that there is a statistically significant difference(p<0.05). The 10-year ASCVD risk of 113 people aged 40-64 years, which were classified in low risk group (<7.5%) and in high risk group (≥7.5%) were assessed by pooled cohort equation and the results shows that risk percentage were 65.14% and 34.86% and there is statistically significant difference in MHR, which were 10.58±4.80 and 14.07±4. 90 in respective groups.@*Conclusions@#Prevalence of dyslipidemia in preventive screening were high in a group of 20-62 years old and the group of those were estimated high The 10-year ASCVD risk, also had relatively higher MHR. Moreover, there is a positive relation between dyslipidemia and MHR. These results show that it is possible to use MHR as a new inflammation marker in ASCVDs for early detection purpose.
ABSTRACT
This consensus established the atherosclerotic process in the adult cardiovascular disease (atherosclerotic cardiovascular diseases, ASCVD) high-risk groups use of Xinnaoning capsule in order to enhance the curative effect of key process, summarized the compatibility theory of traditional Chinese medicine, the pharmaceutical and pharmacological research characteristics of Xinnaoning Capsule, defined the accurate applicable people, the intervention time and curative effect of disease characteristics and optimization solutions of Xinnaoning Capsule, summarized the adverse reactions, taboo, matters needing attention, and non-clinical safety and other relevant evidence of Xinnaoning Capsule. This consensus is suitable for practicing physicians, practicing physicians of traditional Chinese medicine, and practicing physicians of integrated traditional Chinese and Western medicine in ASCVD related professional fields.
ABSTRACT
Statins are important drugs for the prevention and treatment of atherosclerotic cardiovascular disease (ASCVD). The role and status of statins in ASCVD secondary prevention have been established, but the application of statins in ASCVD primary prevention in the elderly is controversial, especially in the elderly aged 75 years and older. The evidence for primary prevention with statins is not adequate. It should be cautious to initiate statins for primary prevention, because of the frailty, multicomobidity, polypharmacy and the limited life expectancy of the elderly may increase the risk of statins adverse reactions. The recent clinical studies and guidelines of statin primary prevention in the elderly population especially in aged 75 years and older have been reviewed in the paper. Making decisions based on fully evaluating the patients' ratio of benefits and risk with patients and implement statin individualized treatment strategies are emphasized.
ABSTRACT
Objectives: Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality. The American College of Cardiology/American Heart Association (ACC/AHA) atherosclerotic cardiovascular disease (ASCVD) risk estimator is a recently developed online calculator tool for primary prevention. Family physicians, as first-line soldiers, have close contact with local community patients making preventive care management an integral part of their routine work. Therefore, we would like to assess primary health care providers’ knowledge, attitude and barriers for using ASCVD risk estimator in a family health care facility. Methods: This was a quantitative, cross-sectional, single-center study which took place at a tertiary health care facility between December 2018 and January 2019. An English-paper-based self-administered questionnaire was distributed to all primary health care physicians (n=172). Results: Most of the participants were using a different type of cardiovascular risk score calculator 128 (97.7%). Among these scores, ASCVD risk assessment calculator was the highest frequently used calculator 67 (51.1%) and Framingham risk score 43 (32.8%). Study participant preferred to use mobile application 102 (77.9%) as a technical method of risk score calculation. ASCVD knowledge was significantly related to participants’ clinical attitude (r=0.3, p-value=0.003) however, they have moderate knowledge about ASCVD risk calculator (61.7%), and only 37.3% have a positive attitude towards it. Conclusion: Health promotion implementation needs using powerful primary prevention of cardiovascular risk calculators. Therefore, enhancing family physician knowledge and eliminate obstacles will gradually improve their attitude towards disease prediction and prevention.
ABSTRACT
Millones de personas, sin indicación médica, toman aspirina para la prevención primaria de la enfermedad ateroesclerótica cardiovascular. La Sociedad Europea de Cardiología no la recomienda para prevención primaria de esta entidad y las Guías del ACC/ AHA sobre Prevención Primaria de la Enfermedad Ateroesclerótica Cardiovascular la recomiendan solo en personas con riesgo cardiovascular aumentado. El beneficio de la aspirina en pacientes con enfermedad cardiovascular establecida sobrepasa el riesgo de sangrado. Ese beneficio se debe al efecto antiinflamatorio y anti-plaquetario, que reduce el riesgo de aterotrombosis, pero con riesgo de sangrado particularmente en individuos susceptibles de sangrar. El papel de esta medicación en individuos sin enfermedad cardiovascular establecida es controversial en especial si tienen riesgo de sangrado. En esta comunicación se discuten las En las Guías del ACC/AHA, el estudio ASCEND en diabéticos, el ASPREE en ancianos sanos y el ARRIVE en pacientes con moderado a alto riesgo y otros para que sirva de alarma a los médicos generales y especialistas, a fin de que indaguen sobre el uso de aspirina en sus pacientes, y al mismo tiempo discutan sobre el balance entre el daño y los beneficios, particularmente en los pacientes ancianos y en aquellos con riesgo de sangrado. Se sugiere realizar un estudio para obtener la evidencia del número de personas que ingieren aspirina automedicada, realizar su seguimiento, y evolución una vez conocidas ampliamente e implementadas las presentes recomendaciones(AU)
Millions of people, without medical indication, take aspirin for the primary prevention of cardiovascular atherosclerotic disease. The European Society of Cardiology does not recommend it for primary prevention, and the ACC/AHA Guidelines on Primary Prevention of Cardiovascular Atherosclerotic Disease recommend it only in people with increased cardiovascular risk. The benefit of aspirin in patients with established cardiovascular disease outweighs the risk of bleeding. This benefit is due to the anti-inflammatory and anti-platelet effect, which reduces the risk of atherothrombosis, but with the risk of bleeding, particularly in individuals susceptible to bleeding. However, the role of this medication as primary prevention in individuals without established cardiovascular disease is controversial especially if they are at risk of bleeding. Despite the recommendations of the ACC/AHA and the European guidelines aspirin continues to be auto medicated for a large number of subjects. In this communication we discuss the ACC / AHA Guidelines, the ASCEND study in diabetics, the ASPREE in healthy elderly and the ARRIVE in patients with moderate to high risk and others to serve as an alarm to general practitioners and specialists, in order for them to inquire about the use of aspirin in their patients, and at the same time discuss the balance between the harm and the benefits, particularly in elderly patients and those at risk of bleeding. It is suggested to conduct a study to obtain evidence of the number of people who take self-medicated aspirin, follow up, and evolution once these recommendations are widely known and implemented(AU)
Subject(s)
Humans , Male , Female , Aged , Aged, 80 and over , Coronary Artery Disease/physiopathology , Coronary Artery Disease/drug therapy , Cardiovascular Diseases/physiopathology , Aspirin/therapeutic use , Aspirin/pharmacokinetics , Cardiology , Embolism and Thrombosis , Internal MedicineABSTRACT
Malignant coronary artery disease (CAD) refers to a severe and extensive atherosclerotic process involving multiple coronary arteries in young individuals (aged <45 years in men and <50 years in women) with a low or no burden of established risk factors. Indians, in general, develop acute myocardial infarction (AMI) about 10 years earlier; AMI rates are threefold to fivefold higher in young Indians than in other populations. Although established CAD risk factors have a predictive value, they do not fully account for the excessive burden of CAD in young Indians. Lipoprotein(a) (Lp(a)) is increasingly recognized as the strongest known genetic risk factor for premature CAD, with high levels observed in Indians with malignant CAD. High Lp(a) levels confer a twofold to threefold risk of CAD—a risk similar to that of established risk factors, including diabetes. South Asians have the second highest Lp(a) levels and the highest risk of AMI from the elevated levels, more than double the risk observed in people of European descent. Approximately 25% of Indians and other South Asians have elevated Lp(a) levels (≥50 mg/dl), rendering Lp(a) a risk factor of great importance, similar to or surpassing diabetes. Lp(a) measurement is ready for clinical use and should be an essential part of all CAD research in Indians.
ABSTRACT
Objective To investigate the association between levels of serum alanine aminotransferase (ALT) and the risks of cardiovascular disease in Chinese. Methods A survey of 10 375 subjects aged 40 or older in Jiading District of Shanghai was performed using cluster sampling. All the subjects were recruited to undergo questionnaire interview, anthropometric measurements, and fasting blood sampling. A total of 8 877 participants were included in the final analyses, including 5 664 females and 3 213 males. The mean age of individuals was ( 58.68 ± 9.22)yearsinmenand(57.65±8.93)yearsinwomen(P＜0.01).10-yearriskforafirsthardatherosclerotic cardiovascular diseases (ASCVD) event was calculated. Results Increased ALT levels were associated with more unfavorable cardiovascular risk profiles and 10-year risk for ASCVD. Increased ALT levels were associated with the prevalence of diabetes mellitus in female participants, while in male participants the prevalence of diabetes mellitus appeared as a U-distribution. The prevalence of hypertension and hyperlipidemia were 66.04%, 52.74%and 64.49%, 47.63% respectively. Increased serum ALT was associated with higher prevalence of 10-year risk for ASCVD. As compared with participants in the first ALT quartile, the risks of 10-year risk for ASCVD were increased by 148%(OR＝2.48, 95%CI 1.78-3.45) and 139%(OR＝2.39, 95%CI 1.78-3.19), respectively in male and female participants. As compared with participants in the first ALT quartile, higher prevalence of 10-year risk for ASCVD were increased by 96%(OR＝1.96, 95%CI 1.30-2.95), while there was no significantly statistical difference in men. Conclusion A high-normal serum ALT level was significantly associated with an increased risk of the cardiovascular disease in middle-aged and elderly Chinese.
ABSTRACT
Management of high blood cholesterol is the key point for the treatment and prevention of Atherosclerotic Cardiovascular Disease (ASCVD). Till 2013, Adult Treatment Panel III (ATP III) report was the guideline for the physician for blood cholesterol management. The main feature of this guideline was to achieve a particular target cholesterol level by lifestyle modification, dietary changes and lipid-lowering drugs. But the recently released American College of Cardiology (ACC) and American Heart Association (AHA) guidelines shifted attention to Statin use at high-, moderate- or low-intensity instead of chasing a cholesterol goal. This article reviews the main features of this new guideline comparing to the previous one, where appropriate.